- Home
- LUCY vs CODX Comparison
LUCY vs CODX Comparison
Compare LUCY & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- CODX
- Stock Information
- Founded
- LUCY 2017
- CODX 2013
- Country
- LUCY United States
- CODX United States
- Employees
- LUCY N/A
- CODX N/A
- Industry
- LUCY Ophthalmic Goods
- CODX Medical/Dental Instruments
- Sector
- LUCY Health Care
- CODX Health Care
- Exchange
- LUCY Nasdaq
- CODX Nasdaq
- Market Cap
- LUCY 8.9M
- CODX 9.8M
- IPO Year
- LUCY 2022
- CODX 2017
- Fundamental
- Price
- LUCY $2.08
- CODX $0.28
- Analyst Decision
- LUCY
- CODX Buy
- Analyst Count
- LUCY 0
- CODX 2
- Target Price
- LUCY N/A
- CODX $5.50
- AVG Volume (30 Days)
- LUCY 5.9M
- CODX 491.4K
- Earning Date
- LUCY 08-11-2025
- CODX 08-07-2025
- Dividend Yield
- LUCY N/A
- CODX N/A
- EPS Growth
- LUCY N/A
- CODX N/A
- EPS
- LUCY N/A
- CODX N/A
- Revenue
- LUCY $1,707,470.00
- CODX $3,497,583.00
- Revenue This Year
- LUCY $367.48
- CODX N/A
- Revenue Next Year
- LUCY $166.67
- CODX $42.11
- P/E Ratio
- LUCY N/A
- CODX N/A
- Revenue Growth
- LUCY 22.75
- CODX N/A
- 52 Week Low
- LUCY $1.57
- CODX $0.23
- 52 Week High
- LUCY $13.20
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- LUCY 42.33
- CODX 43.19
- Support Level
- LUCY $1.95
- CODX $0.26
- Resistance Level
- LUCY $4.97
- CODX $0.29
- Average True Range (ATR)
- LUCY 0.35
- CODX 0.02
- MACD
- LUCY -0.09
- CODX 0.00
- Stochastic Oscillator
- LUCY 4.46
- CODX 26.83
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.